EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis

Yung-Yu Hsieh iD, Wei-Ming Chen iD, Kao-Chi Chang, Te-Sheng Chang iD, Chao-Hung Hung iD, Yao-Hsu Yang iD, Shui-Yi Tung, Kuo-Liang Wei iD, Chen-Heng Shen, Cheng-Shyong Wu, Yuan-Jie Ding, Jing-Hong Hu und 5 weitere

Viruses · 2023

DOI: 10.3390/v15010252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Yung-Yu Hsieh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi 613016, Taiwan. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Hepatitis C, Chronic, Hepatitis C, Liver Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiayi Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The real-world benefits of direct-acting antiviral (DAA)-induced sustained virologic response (SVR) on the de novo occurrence and progression of esophageal varices (EV) remain unclear in patients with hepatitis C virus (HCV)-related liver cirrhosis (LC). This is a retrospective cohort study evaluating all patients with Child-Pugh class A HCV-related LC during 2013 to 2020 in the Chang Gung Medical System. A total of 215 patients fit the inclusion criteria and were enrolled. Of them, 132 (61.4%) patients achieved DAA induced-SVR and 83 (38.6%) did not receive anti-viral treatment. During a median follow-up of 18.4 (interquartile range, 10.1–30.9) months, the 2-year incidence of de novo EV occurrence was 8 (7.0%) in the SVR group and 7 (12.7%) in the treatment-naïve group. Compared to the treatment-naïve group, the SVR group was associated with a significantly lower incidence of EV occurrence (adjusted hazard ratio [aHR]: 0.47, p = 0.030) and a significantly lower incidence of EV progression (aHR: 0.55, p = 0.033). The risk of EV progression was strongly correlated with the presence of baseline EV (p < 0.001). To the best of our knowledge, this is the first study to demonstrate that DAA-induced SVR is associated with decreased risk of de novo EV occurrence and progression in the real world.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal and Gastric VaricesHepatitis C, ChronicHepatitis CLiver NeoplasmsCarcinoma, HepatocellularHumansAntiviral AgentsHepacivirusRetrospective StudiesLiver Cirrhosis

Stichwörter der Autor:innen

direct-acting antiviralesophageal varicesliver cirrhosisportal hypertensionsustained virologic response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833253, Taiwan.
  • Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.

ORCID-Profile: Yung-Yu Hsieh, Wei-Ming Chen, Te-Sheng Chang, Chao-Hung Hung, Yao-Hsu Yang, Kuo-Liang Wei, Meng-Hung Lin, Chung-Kuang Lu, Ming-Shyan Lin

Förderung

  • Chiayi Chang Gung Memorial Hospital

Zitieren

APA

Hsieh, Y. Y., Chen, W. M., Chang, K. C., Chang, T. S., Hung, C. H., Yang, Y. H., Tung, S. Y., Wei, K. L., Shen, C. H., Wu, C. S., Ding, Y. J., Hu, J. H., Huang, Y. T., Lin, M. H., Lu, C. K., Lin, Y. H., & Lin, M. S. (2023). Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis. Viruses. https://doi.org/10.3390/v15010252

Vancouver

Hsieh YY, Chen WM, Chang KC, Chang TS, Hung CH, Yang YH, et al. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis. Viruses. 2023. doi:10.3390/v15010252

BibTeX
@article{Hsieh2023,
  author = {Hsieh, Yung-Yu and Chen, Wei-Ming and Chang, Kao-Chi and Chang, Te-Sheng and Hung, Chao-Hung and Yang, Yao-Hsu and Tung, Shui-Yi and Wei, Kuo-Liang and Shen, Chen-Heng and Wu, Cheng-Shyong and Ding, Yuan-Jie and Hu, Jing-Hong and Huang, Yu-Ting and Lin, Meng-Hung and Lu, Chung-Kuang and Lin, Yi-Hsiung and Lin, Ming-Shyan},
  title = {Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15010252}
}
Kostenlos starten →